Rockwell Medical (RMTI) vs TransCode Therapeutics (RNAZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rockwell Medical (RMTI) has outperformed TransCode Therapeutics (RNAZ) over the past year, losing 33.7% versus a loss of 88.4%. Over five years, RMTI leads with a -87.8% price change compared with -100.0% for RNAZ. Rockwell Medical is the larger company by market cap ($32.3 million vs $29.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RMTI | RNAZ |
|---|---|---|
| Share price | $8.02 | $1.71 |
| Market cap | $32.32M | $28.95M |
| 1-day change | -2.43% | -2.84% |
| YTD return | -3.37% | -74.96% |
| 1-year return | -33.72% | -88.45% |
| 5-year return | -87.85% | -100.00% |
| Forward P/E | 114.57 | — |
| EPS (TTM) | $-1.34 | $-52.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.90 | $15.94 |
| 52-week low | $4.89 | $1.52 |
| Distance from 52-week high | -37.83% | -89.27% |
| Analyst consensus | none | — |
| Avg. price target upside | +149.38% | — |
| Average volume | 26.80K | 50.19K |
| Shares outstanding | 4.03M | 16.93M |
| Employees | 157 | 12 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RMTI has outperformed RNAZ by 54.7 percentage points over the past year.
About Rockwell Medical
RMTI stock →Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers.
Healthcare · Drug Manufacturers - Specialty & Generic · 157 employees
About TransCode Therapeutics
RNAZ stock →TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.
Healthcare · Biotechnology · 12 employees
RMTI vs RNAZ FAQ
Which is bigger, Rockwell Medical or TransCode Therapeutics?
Rockwell Medical (RMTI) is larger, with a market capitalization of $32.32M compared with $28.95M for TransCode Therapeutics (RNAZ).
Which stock has performed better over the past year, RMTI or RNAZ?
RMTI returned -33.72% over the past 12 months, compared with -88.45% for RNAZ (price return, excluding dividends). Past performance does not predict future results.
Are Rockwell Medical and TransCode Therapeutics in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for Rockwell Medical and Biotechnology for TransCode Therapeutics.